Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
ChromaDex Corp. (NASDAQ: CDXC), transitioning to the name Niagen Bioscience, Inc. with a new Nasdaq ticker symbol NAGE, generates a steady flow of news centered on NAD+ science and healthy aging. As the self-described global authority on nicotinamide adenine dinucleotide (NAD+), the company regularly issues updates on its Niagen ingredient, Tru Niagen supplement brand, and pharmaceutical-grade Niagen IV and injection products.
News for CDXC often includes financial results and outlooks, where ChromaDex reports quarterly and annual net sales, gross margins, net income, and cash flow metrics, along with commentary on trends in Tru Niagen and Niagen ingredient sales. These releases may also discuss expectations for future revenue growth, margin performance, and planned investments in research, development, and marketing.
Investors can also expect corporate and investor relations announcements, such as participation in healthcare and growth company conferences, investor summits, and panel discussions on longevity and supplementation. These events typically feature company management presenting ChromaDex’s strategy, financial performance, and updates on its NAD+ research and product pipeline.
Another key category of news involves product and partnership developments. ChromaDex has announced the expansion of Niagen IV and related pharmaceutical-grade Niagen products across wellness clinic networks, as well as collaborations where Niagen serves as a hero ingredient in third‑party longevity supplements. The company also highlights recognition in industry lists and awards related to health products and business impact.
Finally, ChromaDex issues scientific and regulatory updates, including information about FDA designations for nicotinamide riboside in rare disease indications and progress toward regulatory milestones. For anyone tracking CDXC, or its successor symbol NAGE, this news feed offers a consolidated view of the company’s financial performance, clinical and regulatory progress, commercial expansion, and branding evolution around Niagen and NAD+ science.
ChromaDex Corp. (NASDAQ:CDXC) announced its key ingredient, Tru Niagen®, is featured in Nestlé Health Science's new Celltrient™ Cellular Energy, a flavored drink mix aimed at enhancing cellular function as we age. The product contains 250mg of Tru Niagen, which effectively raises NAD+ levels, crucial for healthy aging. This launch marks the first product stemming from a global supply agreement established in December 2018 between ChromaDex and Nestlé Health Science. ChromaDex continues to promote the benefits of Tru Niagen through clinical research.
ChromaDex Corp. (NASDAQ:CDXC) announced findings from a study published in Nature Immunology, demonstrating that nicotinamide riboside (NR) enhances tumor-infiltrating T-cells (TILs) in mice. NR improved T-cell function, crucial for new cancer immunotherapies, by preventing mitochondrial dysfunction. Mice treated with NR showed reduced tumor growth and increased effectiveness when combined with immunotherapy. The study indicates NR's potential to support T-cell immunotherapies for solid tumors, building on previous research linking NR to immune cell maturation and chemotherapy resistance.
ChromaDex Corp. (NASDAQ:CDXC) revealed results from a Phase 2 study published on medRxiv.org, showing a 29% reduction in recovery time for COVID-19 patients. The study reported that patients receiving a nutritional protocol including nicotinamide riboside (NR) experienced an average recovery time of 6.6 days, down from 9.3 days in the placebo group. The research, conducted with ScandiBio Therapeutics, involved 100 patients and demonstrated improved liver function and benign adverse effects. ChromaDex is planning further clinical studies, including a Phase 3 trial.